Microwave Responsive Nanoplatform via P-Selectin Mediated Drug Delivery for Treatment of Hepatocellular Carcinoma with Distant Metastasis

• DOI: 10.1021/acs.nanolett.8b05202
• Publication Date: 2019-04-01T08:50:56Z
• Authors: Jinshun Xu; Xueqing Cheng; Longfei Tan; Changhui Fu; Muneeb Ahmed; Jie Tian; Jianping Dou; Qunfang Zhou; Xiangling Ren; Qiong Wu; Shunsong Tang; Hongqiao Zhou; Xianwei Meng; Jie Yu; Ping Liang
• Keywords: 0301 basic medicine; Carcinoma, Hepatocellular; Lung Neoplasms; Liver Neoplasms; 3. Good health; Drug Liberation; P-Selectin; 03 medical and health sciences; Drug Delivery Systems; Doxorubicin; Cell Line, Tumor; Liposomes; Lactates; Humans; Nanoparticles; Neoplasm Metastasis; Microwaves

Hepatocellular carcinoma (HCC) with metastatic disease is associated a low survival in clinical practice. Many curative options including liver resection, transplantation, and thermal ablation are effective local but limited for patients distant metastasis. In this study, the efficacy, specificity, safety of P-selectin targeted delivery microwave (MW) responsive drug release investigated development HCC therapy. By encapsulating doxorubicin (DOX) MW sensitizer (1-butyl-3-methylimidazolium-l-lactate, BML) into fucoidan conjugated liposomal nanoparticles (TBP@DOX), specific accumulation prominent DOX orthotopic lung metastasis achieved adjuvant exposure. This results growth inhibition that not only 1.95-fold higher than found nontargeted BP@DOX 1.6-fold nonstimuli TP@DOX also equivalent to treatment free at 10-fold dose. Furthermore, optimum anticancer efficacy against prevention widespread dissemination prolonged described. addition, no adverse metabolic events identified using TBP@DOX nanodelivery system despite these being commonly observed traditional chemotherapy. Therefore, administering exposure could potentially enhance therapeutic thermal-chemotherapy HCC, especially those advanced stages.